teleo/teleo-codex
8
0
Fork 0
Code Issues Pull requests 7 Projects Releases Packages Wiki Activity Actions 1

vida: extract 5 claims from Bessemer State of Health AI 2026 + enrich funding claim

Browse source 
- What: 5 new claims from Bessemer report, 1 enrichment to existing funding claim, _map.md updated
- Why: Phase 2 extraction — Leo assigned Bessemer report as primary source
- New claims: consumer cash-pay adoption, AI-native unit economics, AI scribe adoption velocity,
  FDA preclinical pivot, CMS AI reimbursement codes
- Enrichment: added Bessemer corroboration data to healthcare AI funding claim

Pentagon-Agent: Vida <F262DDD9-5164-481E-AA93-865D22EC99C0>

Co-Authored-By: Claude Opus 4.6 <noreply@anthropic.com>
This commit is contained in:
m3taversal 2026-03-06 16:20:50 +00:00
parent 44ee32ca62
commit 84c39e10b6
2 changed files with 8 additions and 1 deletions
Show stats Download patch file Download diff file Expand all files Collapse all files

5
domains/health/_map.md
View file

@ -24,6 +24,9 @@ Vida's domain spans the structural transformation of healthcare from reactive si
- [[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]] — the benchmark-to-clinical gap - [[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]] — the benchmark-to-clinical gap
- [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]] — physician overrides degrade AI from 90% to 68% - [[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]] — physician overrides degrade AI from 90% to 68%
- [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — Wachter's physician-licensing model for AI regulation - [[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]] — Wachter's physician-licensing model for AI regulation
- [[AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk]] — fastest-adopting clinical AI category; beachhead for broader AI trust
- [[AI-native health companies achieve 3-5x the revenue productivity of traditional health services because AI eliminates the linear scaling constraint between headcount and output]] — structural unit economics shift: $500K-1M+ ARR/FTE vs $100-200K
- [[consumer willingness to pay out of pocket for AI-enhanced care is outpacing reimbursement creating a cash-pay adoption pathway that bypasses traditional payer gatekeeping]] — RadNet: 36% pay OOP for AI mammography, 43% higher detection
## Value-Based Care & Devoted Health ## Value-Based Care & Devoted Health
- [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening]] — proof of concept for purpose-built payvidor model during CMS tightening - [[Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening]] — proof of concept for purpose-built payvidor model during CMS tightening
@ -41,6 +44,7 @@ Vida's domain spans the structural transformation of healthcare from reactive si
- [[gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment]] — scalability breakthrough for curative medicine - [[gene editing is shifting from ex vivo to in vivo delivery via lipid nanoparticles which will reduce curative therapy costs from millions to hundreds of thousands per treatment]] — scalability breakthrough for curative medicine
- [[personalized mRNA cancer vaccines show sustained 49 percent reduction in melanoma recurrence after five years representing a genuinely novel therapeutic paradigm]] — mRNA platform beyond COVID - [[personalized mRNA cancer vaccines show sustained 49 percent reduction in melanoma recurrence after five years representing a genuinely novel therapeutic paradigm]] — mRNA platform beyond COVID
- [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] — net cost trajectory: inflationary through transition - [[the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline]] — net cost trajectory: inflationary through transition
- [[FDA is replacing animal testing with AI models and organ-on-chip as the default preclinical pathway which will compress drug development timelines and reduce the 90 percent clinical failure rate]] — FDA April 2025 roadmap: animal studies to become "exception" within 3-5 years
## Mental Health & Digital Therapeutics ## Mental Health & Digital Therapeutics
- [[prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost without the pricing power that justifies it for near-zero marginal cost software]] — Pear, Akili, Woebot: the DTx autopsy - [[prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost without the pricing power that justifies it for near-zero marginal cost software]] — Pear, Akili, Woebot: the DTx autopsy
@ -54,6 +58,7 @@ Vida's domain spans the structural transformation of healthcare from reactive si
- [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]] — CMS targeting acquisition-based vertical integration - [[CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring]] — CMS targeting acquisition-based vertical integration
- [[anti-payvidor legislation targets all insurer-provider integration without distinguishing acquisition-based arbitrage from purpose-built care delivery]] — structural separation bills threatening payvidor model - [[anti-payvidor legislation targets all insurer-provider integration without distinguishing acquisition-based arbitrage from purpose-built care delivery]] — structural separation bills threatening payvidor model
- [[Kaiser Permanentes 80-year tripartite structure is the strongest precedent for purpose-built payvidor exemptions because any structural separation bill that captures Kaiser faces 12.5 million members and Californias entire healthcare infrastructure]] — Kaiser's 80-year precedent for purpose-built integration - [[Kaiser Permanentes 80-year tripartite structure is the strongest precedent for purpose-built payvidor exemptions because any structural separation bill that captures Kaiser faces 12.5 million members and Californias entire healthcare infrastructure]] — Kaiser's 80-year precedent for purpose-built integration
- [[CMS is creating AI-specific reimbursement codes which will formalize a two-speed adoption system where proven AI applications get payment parity while experimental ones remain in cash-pay limbo]] — category I/III CPT codes for AI-assisted diagnosis
## Epidemiological Transition & Risk Landscape ## Epidemiological Transition & Risk Landscape
- [[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]] — the fundamental discontinuity - [[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]] — the fundamental discontinuity

4
domains/health/healthcare AI funding follows a winner-take-most pattern with category leaders absorbing capital at unprecedented velocity while 35 percent of deals are flat or down rounds.md
View file

@ -3,7 +3,7 @@ description: Global healthcare venture financing reached 60.4 billion in 2025 bu
type: claim type: claim
domain: health domain: health
created: 2026-02-17 created: 2026-02-17
source: "Health tech VC landscape analysis February 2026; OpenEvidence Abridge Hippocratic AI fundraising disclosures; Agilon Health SEC filings; Rock Health digital health funding reports 2025" source: "Health tech VC landscape analysis February 2026; OpenEvidence Abridge Hippocratic AI fundraising disclosures; Agilon Health SEC filings; Rock Health digital health funding reports 2025; Bessemer Venture Partners State of Health AI 2026"
confidence: likely confidence: likely
--- ---
@ -17,6 +17,8 @@ Global healthcare venture financing reached $60.4 billion in 2025, the strongest
The emerging consensus: healthcare AI is a platform shift, not a bubble, but the shift creates winner-take-most dynamics where category leaders absorb capital while everyone else fights for scraps. The IPO window is opening cautiously (Hinge Health at ~60% discount, Insilico Medicine in Hong Kong). 2026 demands fundamentals: clinical-grade evidence, regulatory clarity, proven path to profitability. 15 new unicorns were minted in 2025, predominantly in AI-enabled categories. The emerging consensus: healthcare AI is a platform shift, not a bubble, but the shift creates winner-take-most dynamics where category leaders absorb capital while everyone else fights for scraps. The IPO window is opening cautiously (Hinge Health at ~60% discount, Insilico Medicine in Hong Kong). 2026 demands fundamentals: clinical-grade evidence, regulatory clarity, proven path to profitability. 15 new unicorns were minted in 2025, predominantly in AI-enabled categories.
**Bessemer corroboration (January 2026):** 527 VC deals in 2025 totaling an estimated $14B deployed. Average deal size increased 42% year-over-year (from $20.7M to $29.3M). Series D+ valuations jumped 63%. AI companies captured 55% of health tech funding (up from 37% in 2024). For every $1 invested in AI broadly, $0.22 goes to healthcare AI — exceeding healthcare's 18% GDP share. The Health Tech 2.0 IPO wave produced 6 companies with $36.6B combined market cap, averaging 67% annualized revenue growth. Health tech M&A hit 400 deals in 2025 (up from 350 in 2024), with strategic acquirers consolidating AI capabilities.
--- ---
Relevant Notes: Relevant Notes: